Thorsten Kühn

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters

Torsten Mattfeldt, Jörg Kotzerke, Gerhard Glatting, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

Peter A Fasching, Mahdi Rezai, Keyur Mehta, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy—results from the prospective multi-center study BRENDA II

Maria Blettner, Lukas Schwentner, Susanne Singer, 2016, Supportive Care in Cancer.

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Carsten Denkert, Manfred Dietel, C. Denkert, 2013, PloS one.